Literature DB >> 18224458

Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy.

Se Hoon Park1, Moon Sook Cho, Young Saing Kim, Junshik Hong, Eunmi Nam, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee, Woon Kee Lee.   

Abstract

PURPOSE: To determine whether patients' self-reported quality-of-life (QOL) parameters could predict survival for patients with advanced gastric cancer (AGC) treated with first-line chemotherapy, we performed this analysis based on the data obtained from 254 patients enrolled in three consecutive prospective randomized trials at a single institution.
METHODS: Consenting patients with AGC received first-line chemotherapy as specified in the protocols. QOL was assessed at baseline using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaires. Baseline univariate and multivariate analyses were performed on the QOL data and the recognized clinical predictors for survival.
RESULTS: Of 254 patients, 164 completed the QOL questionnaire at baseline. All patients received fluorouracil-containing first-line chemotherapy for AGC. With 88% observed deaths and a reported median survival of 9.5 months [95% confidence interval (CI) 8.8-10.2 months], there were no significant differences in survival between patients with or without QOL data. The final Cox multivariate model revealed four prognostic factors: age [hazard ratio (HR) 2.08, 95% CI 1.32-3.33, P = 0.002], bone metastasis (HR 2.70, 95% CI 1.30-5.56, P = 0.008), hemoglobin (HR 0.58, 95% CI 0.37-0.92, P = 0.020), and social functioning (HR 0.40, 95% CI 0.23-0.64, P = 0.001). When adjusting for clinical parameters, social functioning was an independently significant prognostic factor for longer survival.
CONCLUSION: Baseline social functioning, along with age, presence of bone metastasis, and baseline hemoglobin level, independently predicts survival of AGC patients treated with first-line chemotherapy. QOL assessment should be routinely included to provide useful prognostic information concerning AGC patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18224458     DOI: 10.1007/s11136-008-9307-8

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  21 in total

1.  Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer.

Authors:  J A Kramer; D Curran; M Piccart; J C de Haes; P Bruning; J Klijn; I Van Hoorebeeck; R Paridaens
Journal:  Eur J Cancer       Date:  2000-08       Impact factor: 9.162

2.  Systemic Chemotherapy in Gastric Cancer: Where Do We Stand Today?

Authors: 
Journal:  Oncologist       Date:  1998

3.  Annual Report of the Korea Central Cancer Registry Program 2000: Based on Registered Data from 131 Hospitals.

Authors:  Jong Myon Bae; Young Joo Won; Kyu Won Jung; Jae Gahb Park
Journal:  Cancer Res Treat       Date:  2002-04       Impact factor: 4.679

4.  Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.

Authors:  Paolo Maione; Francesco Perrone; Ciro Gallo; Luigi Manzione; FrancoVito Piantedosi; Santi Barbera; Silvio Cigolari; Francesco Rosetti; Elena Piazza; Sergio Federico Robbiati; Oscar Bertetto; Silvia Novello; Maria Rita Migliorino; Adolfo Favaretto; Mario Spatafora; Francesco Ferraù; Luciano Frontini; Alessandra Bearz; Lazzaro Repetto; Cesare Gridelli; Emiddio Barletta; Maria Luisa Barzelloni; Rosario Vincenzo Iaffaioli; Ermelinda De Maio; Massimo Di Maio; Gianfranco De Feo; Giuseppe Sigoriello; Paolo Chiodini; Angela Cioffi; Vincenzo Guardasole; Valentina Angelini; Antonio Rossi; Domenico Bilancia; Domenico Germano; Alfredo Lamberti; Vittorio Pontillo; Luigi Brancaccio; Francesco Renda; Francesco Romano; Gabriella Esani; Anna Gambaro; Orazio Vinante; Giuseppe Azzarello; Maurizia Clerici; Roberto Bollina; Paolo Belloni; Mirella Sannicolò; Libero Ciuffreda; Giuseppe Parello; Mary Cabiddu; Cosimo Sacco; Angela Sibau; Gianfranco Porcile; Federico Castiglione; Oliviero Ostellino; Silvio Monfardini; Micaela Stefani; Giorgio Scagliotti; Giovanni Selvaggi; Filippo De Marinis; Olga Martelli; Giampietro Gasparini; Alessandro Morabito; Domenico Gattuso; Giuseppe Colucci; Domenico Galetta; Francesco Giotta; Vittorio Gebbia; Nicola Borsellino; Antonio Testa; Emilia Malaponte; Matteo A Capuano; Michele Angiolillo; Francesco Sollitto; Umberto Tirelli; Simona Spazzapan; Vincenzo Adamo; Giuseppe Altavilla; Antonio Scimone; Maria Raffaella Hopps; Francesco Tartamella; Giovanni Pietro Ianniello; Vincenza Tinessa; Giuseppe Failla; Roberto Bordonaro; Nicola Gebbia; Maria Rosaria Valerio; Modesto D'Aprile; Enzo Veltri; Maurizio Tonato; Samir Darwish; Sante Romito; Francesco Carrozza; Sandro Barni; Antonio Ardizzoia; Giuliana Mara Corradini; Gianfranco Pavia; Mario Belli; Giuseppe Colantuoni; Enzo Galligioni; Orazio Caffo; Roberto Labianca; Antonello Quadri; Enrico Cortesi; Giuliana D'Auria; Sergio Fava; Anna Calcagno; Gino Luporini; M Cristina Locatelli; Francesco Di Costanzo; Silvia Gasperoni; Luciano Isa; Paola Candido; Fernando Gaion; Giovanni Palazzolo; Giuseppe Nettis; Anselmo Annamaria; Massimo Rinaldi; Massimo Lopez; Raffaella Felletti; Giorgio Bernabò Di Negro; Nestore Rossi; Antonio Calandriello; Luigi Maiorino; Rodolfo Mattioli; Alfredo Celano; Stefania Schiavon; Alfonso Illiano; Carlo Alberto Raucci; Michele Caruso; Paolo Foa; Giuseppe Tonini; Carlo Curcio; Marina Cazzaniga
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

5.  Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma.

Authors:  J Lee; T Lim; J E Uhm; K W Park; S H Park; S C Lee; J O Park; Y S Park; H Y Lim; T S Sohn; J H Noh; J S Heo; C K Park; S Kim; W K Kang
Journal:  Ann Oncol       Date:  2007-02-13       Impact factor: 32.976

6.  Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.

Authors:  Ian Chau; Andy R Norman; David Cunningham; Justin S Waters; Jacqui Oates; Paul J Ross
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

7.  A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer.

Authors:  Se Hoon Park; Eunmi Nam; Soo-Mee Bang; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee
Journal:  Cancer Chemother Pharmacol       Date:  2007-08-10       Impact factor: 3.333

8.  Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer.

Authors:  S H Park; E Nam; J Park; E K Cho; D B Shin; J H Lee; W K Lee; M Chung; S I Lee
Journal:  Ann Oncol       Date:  2007-12-13       Impact factor: 32.976

Review 9.  The treatment of advanced gastric cancer: new findings on the activity of the taxanes.

Authors:  Eric Van Cutsem
Journal:  Oncologist       Date:  2004

10.  Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

Authors:  S Pyrhönen; T Kuitunen; P Nyandoto; M Kouri
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

View more
  13 in total

1.  Therapeutic effect of Jinlongshe Granule () on quality of life of stage IV gastric cancer patients using EORTC QLQ-C30: A double-blind placebo-controlled clinical trial.

Authors:  Da-zhi Sun; Jian-peng Jiao; Xuan Zhang; Jing-yu Xu; Min Ye; Li-juan Xiu; Ying Zhao; Ye Lu; Xuan Liu; Jing Zhao; Jun Shi; Zhi-feng Qin; Pin-kang Wei
Journal:  Chin J Integr Med       Date:  2014-11-16       Impact factor: 1.978

2.  Statistical methodology is crucial in prognostic factor analysis of health-related quality of life.

Authors:  M E Mauer; A Bottomley; C Coens
Journal:  Qual Life Res       Date:  2008-05-24       Impact factor: 4.147

Review 3.  Patient-reported outcomes as end points and outcome indicators in solid tumours.

Authors:  Angeles A Secord; Robert L Coleman; Laura J Havrilesky; Amy P Abernethy; Gregory P Samsa; David Cella
Journal:  Nat Rev Clin Oncol       Date:  2015-03-10       Impact factor: 66.675

4.  Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma.

Authors:  Andrew J Martin; Emma Gibbs; Katrin Sjoquist; Nick Pavlakis; John Simes; Tim Price; Jenny Shannon; Sanjeev Gill; Vikram Jain; Geoffrey Liu; George Kannourakis; Yeul Hong Kim; Jin Won Kim; David Goldstein
Journal:  Gastric Cancer       Date:  2017-08-16       Impact factor: 7.370

5.  Health-related quality of life and cancer clinical trials.

Authors:  David Osoba
Journal:  Ther Adv Med Oncol       Date:  2011-03       Impact factor: 8.168

6.  EORTC QLQ-C15-PAL quality of life score as a prognostic indicator of survival in patients with far advanced cancer.

Authors:  Yong Joo Lee; Sang-Yeon Suh; Youn Seon Choi; Jae Yong Shim; Ah-Ram Seo; Sung-Eun Choi; Hong-Yup Ahn; Eunji Yim
Journal:  Support Care Cancer       Date:  2014-03-01       Impact factor: 3.603

7.  Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer.

Authors:  Yingwei Qi; Steven E Schild; Sumithra J Mandrekar; Angelina D Tan; James E Krook; Kendrith M Rowland; Yolanda I Garces; Gamini S Soori; Alex A Adjei; Jeff A Sloan
Journal:  J Thorac Oncol       Date:  2009-09       Impact factor: 15.609

Review 8.  The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer.

Authors:  Rutika Mehta; Anuhya Kommalapati; Richard D Kim
Journal:  Cancer Manag Res       Date:  2020-01-07       Impact factor: 3.989

Review 9.  Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008.

Authors:  Ali Montazeri
Journal:  Health Qual Life Outcomes       Date:  2009-12-23       Impact factor: 3.186

10.  Health-Related Quality of Life and Survival Outcomes of Pediatric Patients With Nonmetastatic Osteosarcoma Treated in Countries With Different Resources.

Authors:  Michael W Bishop; Shailesh M Advani; Milena Villarroel; Catherine A Billups; Fariba Navid; Cecilia Rivera; Juan A Quintana; Jami S Gattuso; Pamela S Hinds; Najat C Daw
Journal:  J Glob Oncol       Date:  2017-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.